Programmed cell death ligand‐1 and cytotoxic T cell infiltrates in metastatic cutaneous squamous cell carcinoma of the head and neck

Head & Neck ◽  
2020 ◽  
Vol 42 (11) ◽  
pp. 3226-3234
Author(s):  
Stefan Kraft ◽  
Shekhar K. Gadkaree ◽  
Daniel G. Deschler ◽  
Derrick T. Lin ◽  
Mai P. Hoang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Death ◽  
T Cell ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Cytotoxic T Cell

Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck

2017 ◽  
Vol 77 (3) ◽  
pp. 527-533 ◽  
Author(s):  
Juana María García-Pedrero ◽  
Pablo Martínez-Camblor ◽  
Susana Diaz-Coto ◽  
Pablo Munguia-Calzada ◽  
Aitana Vallina-Alvarez ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Nodal Metastasis ◽  
Cutaneous Squamous Cell Carcinoma

scholarly journals High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Min Hee Hong ◽  
Su-Jin Shin ◽  
Sung Kwan Shin ◽  
Dae Joon Kim ◽  
Jae Ill Zo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Death ◽  
T Cell ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lymphocyte Activation ◽  
Tissue Microarrays ◽  
T Cell Subsets ◽  
Oesophageal Squamous Cell Carcinoma

AbstractWith the increasing oncological potential of immunotherapy, several immune checkpoint modulators are being investigated. The value of immune markers, including programmed cell death ligand-1, programmed cell death-1 (PD-1), inducible co-stimulator (ICOS), lymphocyte activation gene-3, T-cell immunoglobulin, and mucin-dominant containing-3 (TIM-3), is not well known. Using tissue microarrays of 396 patients who underwent surgery for oesophageal squamous cell carcinoma (ESCC), infiltrated T-cell subsets (CD3, CD8, and Foxp3) and checkpoint protein expression were scored. With a median follow-up of 24.8 months, CD3+ TIL subsets (50.0%) had longer median recurrence-free survival (RFS, 55.0 vs 21.4 months) and overall survival (OS, 77.7 vs 35.8 months). Patients with high ICOS expression (46.5%) had longer median RFS (53.9 vs 25.3 months) and OS (88.8 vs 36.9 months). For PD-1, RFS (hazard ratio [HR] 0.67) and OS (HR 0.66) were significantly longer in the high-expression group (45.2%). In the multivariate analysis, high TIM-3 expression (50.8%) had a significant relationship with shorter RFS (HR = 1.52) and OS (HR = 1.60). High CD3+ TIL and T-cell ICOS expression were associated with favourable prognosis, whereas high TIM-3 expression suggested a poor prognosis. Our findings may confer new insights to improve ESCC outcomes beyond the application of PD-1 blockade.

Sign in / Sign up

Export Citation Format

Share Document